Insulin resistance and cardiovascular events with low HDL cholesterol: The veterans affairs HDL intervention trial (VA-HIT)

Diabetes Care

Volumn 26, Issue 5, 2003, Pages 1513-1517

  Robins, Sander J ^a   Rubins, Hanna Bloomfield ^b   Faas, Fred H ^c   Schaefer, Ernst J ^d   Elam, Marshall B ^e   Anderson, James W ^f   Collins, Dorothea ^g  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f LEXINGTON VA MEDICAL CENTER   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; HEART DEATH; HEART INFARCTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONBIOLOGICAL MODEL; STROKE;

ANTILIPEMIC AGENTS; BODY CONSTITUTION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GEMFIBROZIL; HUMANS; INSULIN RESISTANCE; MALE; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RISK FACTORS; SURVIVAL ANALYSIS; TRIGLYCERIDES;

EID: 0042669791     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.5.1513     Document Type: Article

References (17)

1. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low HDL-cholesterol. N Engl J Med 341:410-418, 1999
2. Rubins HB, Robins SJ, Collins D: The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol 78:572-575, 1996
3. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285:1585-1591, 2001
4. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW: Diabetes, plasma insulin and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162:2597-2604, 2002
5. Rubins HB, Robins SJ, Iwane MK, Boden WE, Elam MB, Fye C, Gordon DJ, Schaefer EJ, Schectman G, Wittes JT: Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 71:45-52, 1993
6. Cox DR: Regression models and life-tables. JR Stat Soc [B] 34:187-202, 1972
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
8. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, Bergeron J, Gaudet D, Tremblay G, Prud'homme D, Nadeau A, Despres JP: Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102:179-184, 2000
9. Tenkanen L, Manttari M, Manninen V: Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 92:1779-1785, 1995
10. Steiner G: Altering triglyceride concentrations changes insulin-glucose relationships in hypertriglyceridemic patients: double-blind study with gemfibrozil with implications for atherosclerosis. Diabetes Care 14:1077-1081, 1991
11. Mussoni L, Mannucci L, Sirtori C, Pazzucconi F, Bonfardeci G, Cimminiello C, Notarbartolo A, Scafidi V, Bittolo Bon G, Alessandrini P, Nenci G, Parise P, Columbo L, Piliego T, Tremoli E: Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis 148:397-406, 1999
12. Idzior-Walus B, Sieradzki J, Rostworowski W, Zdrienicka A, Kawalec E, Wojcik J, Zarnecki A, Blanc G: Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 30:871-878, 2000
13. Jeng C-Y, Sheu W H-H, Fuh M M-T, Shieh SM, Chen YDI, Reaven GM: Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. J Clin Endocrinol Metab 81:2550-2553, 1996
14. Robins SJ: Fibrates and coronary heart disease reduction in diabetes. Curr Opin Endocrinol Diabetes 9:312-322, 2002
15. Zavaroni I, Bonora E, Pagliara M, Dall'Aglio E, Luchetti L, Buonanno G, Bonati PA, Bergonzani M, Gnudi L, Passeri M, Reaven G: Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 320:702-706, 1989
16. Despres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
17. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J: Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 100:123-128, 1999